Background: In glomerulonephritides, dysmorphic red blood cells (RBCs) with membrane blebs can be found in the urine; this is referred to as glomerular hematuria. Glomerulonephritides are characterized by increased carbonyl stress and elevated methylglyoxal (MGO) levels. MGO causes oxidative stress and intracellular calcium accumulation. In the present study, we investigated whether the effect of MGO-induced calcium accumulation in RBCs develops through increased oxidative stress. Furthermore, we studied whether MGO can lead to RBC membrane blebbing. Methods: RBC suspensions from healthy volunteers were incubated with different concentrations of MGO at 37°C. We measured oxidative stress and intracellular calcium level using fluorescent indicators. We determined the frequency of dysmorphic RBCs, and also performed scanning electron microscopy. Results: MGO increased oxidative stress and caused accumulation of calcium in isolated RBCs. These effects could be prevented using antioxidants. In the presence of MGO, RBC membrane blebbing developed. Conclusion: According to our findings, MGO causes calcium accumulation through oxidative stress. Carbonyl and oxidative stress may play an important role in the formation of dysmorphic RBCs in glomerular hematuria.

Keywords:
Red blood cell, Glomerular hematuria, Methylglyoxal, Oxidative stress, Calcium
1.
Schurek HJ: Mechanisms of glomerular proteinuria and haematuria. Kidney Int 1994;47(suppl):S12–S16.
2.
Mouradian JA, Sherman RL: Passage of an erythrocyte through a glomerular basement membrane gap. New Engl J Med 1975;293:940–941.
3.
Rath B, Turner C, Hartley B, Chantler C: What makes red cells dysmorphic in glomerular haematuria? Pediatr Nephrol 1992;6:424–427.
4.
Túri S, Németh I, Torkos A, Sághy L, Varga I, Matkovics B, Nagy J: Oxidative stress and antioxidant defense mechanism in glomerular diseases. Free Radic Biol Med 1997;22:161–168.
5.
Glomb MA, Tschirnich R: Detection of alpha-dicarbonyl compounds in Maillard reaction systems and in vivo. J Agric Food Chem 2001;49:5543–5550.
6.
Thornalley PJ, Langborg A, Minhas HS: Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999;344:109–116.
7.
Kalapos MP: Methylglyoxal in living organisms. Chemistry, biochemistry, toxicology and biological implications. Toxicol Lett 1999;110:145–175.
8.
Suzuki D, Miyata T, Saotome N, Horie K, Inagi R, Yasuda Y, Uchida K, Izuhara Y, Yagame M, Sakai H, Kurokawa K: Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 1999;10:822–832.
9.
Kempe DS, Lang PA, Duranton C, Akel A, Lang KS, Huber SM, Wieder T, Lang F: Enhanced programmed cell death of iron-deficient erythrocytes. FASEB J 2006;20:368–370.
10.
Cook LJ, Davies J, Yates AP, Elliott AC, Lovell J, Joule JA, Pemberton P, Thornalley PJ, Best L: Effects of methylglyoxal on rat pancreatic β-cells. Biochem Pharmacol 1998;55:1361–1367.
11.
Vasdev S, Ford CA, Longerich L, Parai S, Gadag V, Wadhawan S: Aldehyde induced hypertension in rats: prevention by N-acetyl cysteine. Artery 1998;23:10–36.
12.
Aiken NR, Galey WR, Satterlee JD: A peroxidation model of human erythrocyte intracellular Ca2+ changes with in vivo cell aging: measurement by 19F-NMR spectroscopy. Biochim Biophys Acta 1995;1270:52–57.
13.
Leoncini G, Signorello MG, Piana A, Carrubba M, Armani U: Hyperactivity and increased hydrogen peroxide formation in platelets of NIDDM patients. Thromb Res 1997;86:153–160.
14.
Grynkiewicz G, Poenie M, Tsien RY: A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985;265:3440–3450.
15.
Schuetz E, Schaefer RM, Heidbreder E, Heidland A: Effect of diuresis on urinary erythrocyte morphology in glomerulonephritis. Klin Wochenschr 1985;63:575–577.
16.
Hahm K, Lukashev ME, Luo Y, Yang WJ, Dolinski BM, Weinreb PH, Simon KJ, Chun Wang L, Leone DR, Lobb RR, McCrann DJ, Allaire NE, Horan GS, Fogo A, Kalluri R, Shield CF 3rd, Sheppard D, Gardner HA, Violette SM: Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am J Pathol 2007;170:110–125.
17.
Lebleu VS, Sugimoto H, Miller CA, Gattone VH 2nd, Kalluri R: Lymphocytes are dispensable for glomerulonephritis but required for renal interstitial fibrosis in matrix defect-induced Alport renal disease. Lab Invest 2008;88:284–292.
18.
Apeland T, Mestad O, Hetland O: Assessment of haematuria: automated urine flowmetry vs. microscopy. Nephrol Dial Transplant 2001;16:1615–1619.
19.
Scharnhorst V, Gerlag PG, Nanlohy Manuhutu ML, van der Graaf F: Urine flow cytometry and detection of glomerular hematuria. Clin Chem Lab Med 2006;44:1330–1334.
20.
Breuer W, Epsztejn S, Cabantchik ZI: Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron (II). J Biol Chem 1995;270:24209–24215.
21.
Espinosa-Mansilla A, Durán-Merás I, Salinas F: High-performance liquid chromatographic-fluorometric determination of glyoxal, methylglyoxal, and diacetyl in urine by prederivatization to pteridinic rings. Anal Biochem 1998;255:263–273.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.